2025-11-05T13:59:01-06:00 2024-12-31 135565207 KPMG LLP TWO MANHATTAN WEST 375 9TH AVENUE NEW YORK NY 10001 990 2024-01-01 800631734 NEW YORK GENOME CENTER INC NEWY 6469777000 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 100131941 NANCY KONG INTERIM CFO 6469777000 2025-10-31 1 0 EVAN W SEEKAMP P01907071 2127589700 2025-10-31 2024 2025-03-06 01:10:19Z TOM MANIATIS 101 AVE OF THE AMERICAS NEW YORK NY 10013 87771537 0 X WWW.NYGENOME.ORG X 2010 DE PROVIDING GLOBAL LEADERSHIP IN HUMAN GENOME RESEARCH AND ITS TRANSLATION INTO CLINICAL CARE. 24 23 284 27 816492 0 81695780 75537348 9712534 4904919 191646 360077 1340469 1540287 92940429 82342631 3387586 2986182 0 0 33690192 37954307 14225 788 1329428 44780821 43402203 81872824 84343480 11067605 -2000849 184052230 166954755 138136156 123038215 45916074 43916540 X OPERATE A STATE-OF-THE-ART, WORLD-CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 0 0 60479500 2986182 4233105 GENOME SEQUENCING: THE NEW YORK GENOME CENTER (NYGC) HAS ONE OF NEW YORK'S LARGEST AND MOST ADVANCED WHOLE GENOME SEQUENCING PROGRAMS, HAVING SEQUENCED OVER 106,885 WHOLE GENOME SAMPLES TO DATE. NYGC'S TWO STATE-OF-THE-ART ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS ARE EACH CAPABLE OF SEQUENCING 20,000 HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). SEE SCHEDULE O. 7674355 671814 CLINICAL SEQUENCING: NYGC'S CLEP/CLIA CERTIFIED CLINICAL LABORATORY IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, MATERNAL CELL CONTAMINATION TESTING, AND ANEUPLOIDY SCREENING. 68153855 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 58 0 1 284 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 24 23 1 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X NANCY KONG 6469777154 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 10013 X TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 40.00 0.00 X X 675040 0 0 RUSSELL L CARSON MBA DIRECTOR & CHAIRMAN 1.00 0.00 X X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 1.00 0.00 X X 0 0 0 HERB PARDES MD DIR. & EXEC. VICE CHAIR (ENDED 4/24) 1.00 0.00 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.00 0.00 X 0 0 0 KATRINA ARMSTRONG MD DIRECTOR 1.00 0.00 X 0 0 0 SELWYN M VICKERS MD DIRECTOR 1.00 0.00 X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.00 0.00 X 0 0 0 DAFNA BAR-SAGI PHD DIRECTOR 1.00 0.00 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.00 0.00 X 0 0 0 KENNETH A DILL PHD DIRECTOR (ENDED 10/24) 1.00 0.00 X 0 0 0 RICHARD P LIFTON MD PHD DIRECTOR 1.00 0.00 X 0 0 0 BARBARA ROSATI PHD DIRECTOR (STARTED 10/24) 1.00 0.00 X 0 0 0 ROBERT A HARRINGTON MD DIRECTOR 1.00 0.00 X 0 0 0 ELI CASDIN DIRECTOR 1.00 0.00 X 0 0 0 NICHOLAS DONOFRIO DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH E EDELMAN DIRECTOR 1.00 0.00 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.00 0.00 X 0 0 0 ANTHONY B EVNIN PHD DIRECTOR 1.00 0.00 X 0 0 0 JOHN P HAVENS DIRECTOR 1.00 0.00 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.00 0.00 X 0 0 0 ALONDRA NELSON PHD DIRECTOR (STARTED 6/24) 1.00 0.00 X 0 0 0 FRANK V SICA DIRECTOR & COMMITTEE CHAIR 1.00 0.00 X 0 0 0 DAVID N SPERGEL PHD DIRECTOR (STARTED 3/24) 1.00 0.00 X 0 0 0 JIM SIMONS PHD DIRECTOR (THROUGH 5/24) 1.00 0.00 X 0 0 0 NANCY A THORNBERRY DIRECTOR 1.00 0.00 X 0 0 0 STEVEN J CORWIN MD DIRECTOR (STARTED 6/24) 1.00 0.00 X 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 40.00 0.00 X 468516 0 46016 MARIA JOANTA CHIEF FINANCIAL OFFICER 40.00 0.00 X 385785 0 51441 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF D 40.00 0.00 X 566991 0 38719 SOREN GERMER SVP, GENOME TECHNOLOGIES 40.00 0.00 X 439717 0 38719 CAROL ASHE CHIEF BUSINESS OFFICER 40.00 0.00 X 438815 0 20817 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLO 40.00 0.00 X 371713 0 30204 THOMAS LEHNER SCI DIR, NEURO DG (THROUGH 11/24) 40.00 0.00 X 372482 0 28896 CHARLES GAGNON CHIEF INFORMATION OFFICER 40.00 0.00 X 341546 0 49771 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGIN 40.00 0.00 X 349593 0 20440 DAYNA M OSCHWALD CHIEF OF STAFF 40.00 0.00 X 294329 0 35757 CHRISTOPHER PHIFER BLACK SR. DIR., RESEARCH COMP. 40.00 0.00 X 263806 0 45444 AVINASH VIJAY ABHYANKAR DIRECTOR, CLINICAL BIOINFORM. 40.00 0.00 X 259321 0 41952 CATHERINE E REEVES SR. DIR., SEQUENCING OPERATIONS 40.00 0.00 X 241489 0 36532 5469143 0 484708 103 0 1 0 DONNELLY MECHANICAL 96-59 222ND STREET QUEENS NY 11429 ENGINEERING SERVICES 783173 GUARDIAN SERVICES INDUSTRIES INC 88005 EXPEDITE WAY CHICAGO IL 60695 CLEANING SERVICES 399966 HOWSON & HOWSON LLP 325 SENTRY PARKWAY EAST BLUE BELL PA 10422 LEGAL SERVICES 360656 SPENCERSTUART 353 N CLARK SUITE 2400 CHICAGO IL 60654 RECRUITING SERVICES 224340 RSM US LLP 30 S 17TH ST SUITE 710 PHILADELPHIA PA 19103 CONSULTING SERVICES 192350 8 2435000 22350611 50751737 310488 75537348 RESEARCH SEQUENCING 541700 4233105 3416613 816492 CLINICAL SEQUENCING 541700 671814 671814 4904919 100871 100871 1683278 1683278 4563829 5428906 -865077 -865077 -865077 259206 0 259206 259206 259206 EDC LOAN RECOGNITION 900099 722086 722086 722086 82342631 4088427 816492 1900364 2668307 2668307 317875 317875 4365188 1956771 1802707 605710 25603693 19579840 5629217 394636 1526695 1130593 349052 47050 3096722 2456982 613345 26395 3362009 2683383 616019 62607 455423 455423 141144 141144 60000 60000 788 788 2615838 2515327 100511 505494 243048 254990 7456 4277629 3862562 415067 360696 360696 13258040 10612675 2532183 113182 457045 406595 48880 1570 107362 80790 24311 2261 290077 195569 92887 1621 6565363 6207285 319367 38711 797641 797641 DIRECT COST OF SEQUENCI 9324415 9324415 RESEARCH 3376498 3376498 RECRUITMENT 332450 19202 313248 477088 155442 294205 27441 84343480 68153855 14860197 1329428 9326778 5408177 3505459 4402079 18649498 16784952 7382860 7076051 1607153 1429249 2491274 2478585 146378144 102893087 46071277 43485057 95017931 85890605 184052230 166954755 7098614 5863554 14803697 13422281 2660000 1940000 113573845 101812380 138136156 123038215 X 20204925 14697417 25711149 29219123 45916074 43916540 184052230 166954755 -2000849 1315 0 X 0 1 X 1 1 1 X 51639109 61556925 53970524 81695780 75537348 324399686 51639109 61556925 53970524 81695780 75537348 324399686 121948446 202451240 3312682 4952174 6714605 6808320 7070064 28857845 742082 258491 228680 13394 1242647 354500178 43395688 0.57110 0.60230 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2020 AMOUNT: $ 741,272. 2021 AMOUNT: $ 258,491. 2022 AMOUNT: $ 228,680. 2023 AMOUNT: $ 13,394. 2024 AMOUNT: $ 0. EVENT SPACE REVENUE - 2020 AMOUNT: $ 810. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 1740 0 1 62456 64196 0 PART II-B, LINE 1: THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2024, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITIONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2024 WAS $1,740. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2024, $2,456 OF THE DUES PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. 3481000 1519000 5000000 3481000 3481000 1.00000 0 0 71396055 38077082 33318973 70433221 61453632 8979589 4548868 3362373 1186495 43485057 SECURITY DEPOSITS 5561947 DEFERRED COMPENSATION RETIREMENT PLAN 265805 OPERATING RIGHT-OF-USE-ASSET 80062853 85890605 RIGHT-OF-USE-LIABILITY 100610678 FINANCING LEASE OBLIGATIONS 1201702 101812380 X 88058852 1315 286000 287315 87771537 -5428906 -5428906 82342631 90058386 286000 5428906 5714906 84343480 0 84343480 PART V, LINE 4: THE THOMAS MANIATIS CHAIR FOR EXCELLENCE AND INNOVATION IN GENOMIC SCIENCE FUND WAS ESTABLISHED TO RECOGNIZE AND HONOR THE INTEGRAL ROLE PLAYED BY THOMAS MANIATIS, PH.D., IN MAKING THE NEW YORK GENOME CENTER A LEADER IN THE FURTHERANCE OF GENOMIC RESEARCH. A DESIGNATED PORTION, APPROXIMATELY 5% OF THE FUND'S EARNINGS ANNUALLY WILL BE MADE AVAILABLE FOR GENERAL EXPENDITURE. THE BOARD OF DIRECTORS HAS DISCRETION TO MAKE ADDITIONAL FUNDS AVAILABLE TO SUPPORT THE ESSENTIAL NEEDS OF THE ORGANIZATION. PART X, LINE 2: NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2024 AND 2023. PART XI, LINE 4B - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE -5,428,906. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE 5,428,906. 1 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 2 PROGRAM SERVICES RESEARCH 127064 NORTH AMERICA 0 1 PROGRAM SERVICES RESEARCH 67729 AFRICA 0 0 PROGRAM SERVICES RESEARCH 33360 EUROPE (INCLUDING ICELAND AND GREENLAND) GRANTMAKING 150110 NORTH AMERICA GRANTMAKING 167765 0 3 0 0 0 3 546028 0 546028 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 114023 WIRE 0 NORTH AMERICA RESEARCH SUBAWARD 36087 WIRE 0 1 1 RESEARCH NORTH AMERICA 1 167765 WIRE 0 0 0 0 0 0 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. PART I, LINE 3: THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. 1 COLUMBIA UNIVERSITY 615 WEST 131ST STREET MC841 NEW YORK NY 100277922 135598093 501(C)(3) 375710 0 RESEARCH SUBAWARD NEW YORK UNIVERSITY 70 WASHINGTON SQUARE SOUTH NEW YORK NY 10012 135562308 501(C)(3) 38422 0 RESEARCH SUBAWARD ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 93797 0 RESEARCH SUBAWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 143729 0 RESEARCH SUBAWARD NYU GROSSMAN SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)(3) 205910 0 RESEARCH SUBAWARD MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 279421 0 RESEARCH SUBAWARD JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)(3) 354063 0 RESEARCH SUBAWARD COLD SPRING HARBOR LABORATORY 1 BUNGTOWN ROAD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 200000 0 RESEARCH SUBAWARD YALE UNIVERSITY 135 COLLEGE STREET NEW HAVEN CT 06510 060646973 501(C)(3) 20951 0 RESEARCH SUBAWARD MOREHOUSE SCHOOL OF MEDICINE INC 720 WESTVIEW DRIVE SW ATLANTA GA 303101458 581438873 501(C)(3) 95176 0 RESEARCH SUBAWARD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 79582 0 RESEARCH SUBAWARD WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK NY 10065 150532082 501(C)(3) 111815 0 RESEARCH SUBAWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA 1111 FRANKLIN STREET OAKLAND CA 94607 943067788 501(C)(3) 37951 0 RESEARCH SUBAWARD RUTGERS THE STATE UNIVERSITY 33 KNIGHTSBRIDGE ROAD C281 PISCATAWAY NJ 08854 226001086 501(C)(3) 65864 0 RESEARCH SUBAWARD 14 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. X X 0 0 0 0 0 0 0 1 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 675040 0 0 0 0 0 0 0 0 0 675040 0 0 0 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF D 566991 0 0 0 0 0 20700 0 18019 0 605710 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 468516 0 0 0 0 0 20700 0 25316 0 514532 0 0 0 SOREN GERMER SVP, GENOME TECHNOLOGIES 439717 0 0 0 0 0 20700 0 18019 0 478436 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 438815 0 0 0 0 0 20700 0 117 0 459632 0 0 0 MARIA JOANTA CHIEF FINANCIAL OFFICER 341190 0 0 0 44595 0 20700 0 30741 0 437226 0 0 0 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLO 371713 0 0 0 0 0 20700 0 9504 0 401917 0 0 0 THOMAS LEHNER SCI DIR, NEURO DG (THROUGH 11/24) 343152 0 0 0 29330 0 13396 0 15500 0 401378 0 0 0 CHARLES GAGNON CHIEF INFORMATION OFFICER 341546 0 0 0 0 0 17590 0 32181 0 391317 0 0 0 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGIN 329545 0 950 0 19098 0 20323 0 117 0 370033 0 0 0 DAYNA M OSCHWALD CHIEF OF STAFF 294329 0 0 0 0 0 17813 0 17944 0 330086 0 0 0 CHRISTOPHER PHIFER BLACK SR. DIR., RESEARCH COMP. 263806 0 0 0 0 0 16263 0 29181 0 309250 0 0 0 AVINASH VIJAY ABHYANKAR DIRECTOR, CLINICAL BIOINFORM. 259321 0 0 0 0 0 15947 0 26005 0 301273 0 0 0 CATHERINE E REEVES SR. DIR., SEQUENCING OPERATIONS 241489 0 0 0 0 0 15413 0 21119 0 278021 0 0 0 PART I, LINE 3 IN 2024, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION, AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED THE REMAINING 20% OF HIS TIME TO HIS OWN RESEARCH LABORATORY AT THE UNRELATED ENTITY, WHERE HE MAINTAINED A LABORATORY AND CONDUCTED INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2024, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO WAS REASONABLE. PART I, LINE 7 CERTAIN INDIVIDUALS LISTED ON SCHEDULE J, PART II RECEIVED DISCRETIONARY BONUSES IN 2024. SILAS MANIATIS FAMILY MEMBER 191812 SALARY+BEN 0 X RESEARCH SUPPLIES 103 310488 FMV 0 1 0 PART I, COLUMN (B) THE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO FURTHER THE UNDERSTANDING OF THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE, AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM TEN FOUNDING & THREE ASSOCIATE MEMBER INSTITUTIONS, AS WELL AS 95 AFFILIATE SCIENTIFIC MEMBERS, TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, NYGC HAS CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., A HIGH-PERFORMANCE COMPUTING INFRASTRUCTURE, SOFTWARE, AND NEXT-GENERATION SEQUENCING INSTRUMENTS), AS WELL AS TECHNOLOGY INNOVATION KNOW-HOW AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITIES IN NEW YORK CITY, ACROSS THE UNITED STATES, AND AROUND THE WORLD, FOSTERING INNOVATION AND KNOWLEDGE EXCHANGE; (II) RECRUITING AND RETAINING DIVERSE, WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH, AND MEDICAL INSTITUTIONS, AS WELL AS THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY, TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED ON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED BY NYGC FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH, AND TECHNOLOGY DEVELOPMENT COMMUNITIES; (VII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL, WHERE EVERY INDIVIDUAL FEELS VALUED AND RESPECTED, REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, RELIGION, OR VETERAN STATUS, AND (VIII) CARRYING OUT ACTIVITIES ANCILLARY TO THESE OBJECTIVES. FORM 990, PART III, LINE 4A & LINE 4B NYGC IS COMMITTED TO ADVANCING GENOMIC SCIENCE TO DRIVE NOVEL BIOMEDICAL DISCOVERIES AND TRANSFORM PATIENT CARE THROUGH PRECISION MEDICINE. RESEARCH AND FACULTY NYGC MAINTAINS A STRONG COMMITMENT TO RECRUITING OUTSTANDING FACULTY WITH BROAD EXPERTISE IN DISEASE GENOMICS, COMPUTATIONAL AND MACHINE LEARNING APPROACHES, ENGINEERING, AND GENOMIC TECHNOLOGIES. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY, AFFILIATE MEMBERS, AND A SCIENTIFIC ADVISORY BOARD (SAB) COMPRISED OF WORLD-LEADERS IN GENOMICS AND WHO BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SCIENTIFIC ADVISORY BOARD, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO PURSUE GROUNDBREAKING DISCOVERIES IN BIOMEDICAL RESEARCH, DRIVING ADVANCEMENTS THAT CAN TRANSFORM HEALTHCARE AND IMPROVE PATIENT OUTCOMES. IN 2024, NYGC SCIENTISTS PUBLISHED 78 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS, ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. TWO OF NYGC'S CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE ONCE AGAIN NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2024 HIGHLY CITED RESEARCHERS LIST FOR THE SIXTH CONSECUTIVE YEAR, A TESTAMENT TO THEIR IMPACTFUL CONTRIBUTIONS AND INFLUENCE IN THEIR RESPECTIVE FIELDS OF STUDY. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2024, NYGC EXPANDED ITS COMMITMENT TO SCIENTIFIC TRAINING WITH THE LAUNCH OF ITS EARLY CAREER DEVELOPMENT PROGRAM FOR POST-BACCALAUREATES. THIS PROGRAM WELCOMED ITS FIRST COHORT OF ASPIRING RESEARCHERS WITH THE OPPORTUNITY TO GAIN HANDS-ON RESEARCH EXPERIENCE IN GENOMICS, COMPUTATIONAL BIOLOGY, TECHNOLOGY INNOVATION, AND CLINICAL GENETIC TESTING. NYGC HAS CONTINUED TO MAKE SIGNIFICANT PROGRESS IN ITS CORE RESEARCH AREAS. NOTEWORTHY EXAMPLES OF THIS PROGRESS INCLUDE: CANCER: NYGC'S SIGNATURE POLYETHNIC-1000 (P-1000) IS A MULTI-INSTITUTIONAL COLLABORATIVE EFFORT LED BY DRS. HAROLD VARMUS AND CHARLES SAWYERS, NYGC'S CANCER GROUP, AND LEADERS FROM ACROSS NEW YORK CITY'S CANCER RESEARCH COMMUNITY, LEVERAGING THE CITY'S EXTRAORDINARY DIVERSITY TO ADVANCE CANCER GENOMICS AND ITS APPLICATION IN CLINICAL CARE. DESIGNED TO DEMOCRATIZE CANCER GENOMICS THROUGH WHOLE-GENOME SEQUENCING, BIOINFORMATIC ANALYSIS, CLINICAL RESEARCH, AND COMMUNITY OUTREACH, P-1000 HAS CREATED A POWERFUL PLATFORM FOR UNDERSTANDING HOW DIFFERENT GENETIC BACKGROUNDS INFLUENCE CANCER. THIS WIDELY RECOGNIZED FRAMEWORK LAID THE FOUNDATION FOR TEAM SAMBAI, RECIPIENT OF THE PRESTIGIOUS CANCER GRAND CHALLENGE (CGC) AWARD. LED BY DR. MELISSA DAVIS, NYGC ASSOCIATE FACULTY MEMBER; DIRECTOR, INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE, MOREHOUSE SCHOOL OF MEDICINE; SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES; DIRECTOR OF HEALTH EQUITY, ENGLANDER INSTITUTE OF PRECISION MEDICINE; AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY, WEILL CORNELL MEDICINE, TEAM SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) UNITES EXPERTS IN CANCER GENOMICS, IMMUNOLOGY, EPIDEMIOLOGY, EXPOSOMICS, AND PATIENT ADVOCACY. SELECTED AS ONE OF ONLY FIVE INTERNATIONAL RESEARCH TEAMS, AND THE SOLE GROUP CHOSEN FROM A HIGHLY COMPETITIVE GLOBAL POOL FOCUSED ON CANCER INEQUITIES - ONE OF THE NINE CGC-IDENTIFIED TOUGHEST CHALLENGES IN CANCER IN 2024 - TEAM SAMBAI WILL RECEIVE UP TO $25 MILLION IN FUNDING TO CARRY THIS VITAL WORK FORWARD. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), AT NYGC, LED BY NYGC CORE FACULTY MEMBER, HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 46 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA, SINGLE CELL AND SPATIALLY-RESOLVED TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF THE CGND'S FOCUS ON ALS RESEARCH TO EXTEND THIS WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. DR. HEMALI PHATNANI'S LAB AT NYGC, IN COLLABORATION WITH THE ALS CONSORTIUM, MADE SIGNIFICANT STRIDES IN ALS RESEARCH IN 2024 BY IDENTIFYING THREE DISTINCT MOLECULAR SUBTYPES OF THE DISEASE. THESE MOLECULAR SUBTYPES WERE FOUND TO CORRELATE WITH SPECIFIC PATTERNS OF GENE EXPRESSION, AND EACH HAD DISTINCT CLINICAL FEATURES. UNDERSTANDING THESE SUBTYPES MAY OFFER NEW AVENUES FOR TARGETED TREATMENTS AND IMPROVING THE PRECISION OF ALS THERAPIES. NEUROPSYCHIATRIC DISEASE: THE NYGC IS LEADING A NEW PROJECT THAT WILL DEVELOP NOVEL ARTIFICIAL INTELLIGENCE FRAMEWORKS AND ADVANCED COMPUTATIONAL INFRASTRUCTURE TO EFFECTIVELY HARNESS THE WEALTH OF INFORMATION CONTAINED IN MEDICAL RECORDS AND GENOMIC DATA, AND DEPLOY THAT KNOWLEDGE IN A NOVEL FRAMEWORK FOR PRECISION PSYCHIATRY. THIS FRAMEWORK WILL BE INTEGRATED, IN COLLABORATION WITH MICHAEL ZODY, PHD, NYGC SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, AND CHARLES GAGNON, NYGC'S CHIEF INFORMATION OFFICER, INTO A DATA COMMONS ESTABLISHED TO DISSEMINATE DATA FROM THE CENTER'S GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) INITIATIVE, A TRANSLATIONAL PLATFORM FOR PRECISION PSYCHIATRY DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE-BASED MENTAL HEALTH CARE, WITH A STRONG EMPHASIS ON DATA SECURITY AND PATIENT PRIVACY. COLLECTIVELY, THESE EFFORTS PROMISE TO SIGNIFICANTLY ADVANCE PRECISION PSYCHIATRY BY ENABLING MORE ACCURATE DISEASE-GENE ASSOCIATIONS AND FACILITATING DEMOCRATIZED DATA SHARING, ALL WHILE UPHOLDING HIGH STANDARDS OF DATA PRIVACY. IN COLLABORATION WITH RESEARCHERS AT COLUMBIA UNIVERSITY IRVING MEDICAL CENTER, ZUCKER HILLSIDE HOSPITAL OF NORTHWELL HEALTH, NEW YORK UNIVERSITY, AND THE UNIVERSITY OF CHICAGO, NYGC WAS AWARDED A GRANT FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH TO ADVANCE PRECISION PSYCHIATRY USING ARTIFICIAL INTELLIGENCE. THE COPPER (CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS) PROJECT WILL INTEGRATE ELECTRONIC HEALTH RECORDS, DETAILED PATIENT INFORMATION, AND GENETIC DATA TO DEVELOP PREDICTIVE MODELS FOR TREATMENT RESPONSE, ILLNESS SEVERITY, AND RISK OF COMORBIDITIES IN INDIVIDUALS WITH PSYCHOSIS. LED BY MICHAEL ZODY, PHD, NYGC'S SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, AND VAIDEHI JOBANPUTRA, PHD, FACMG, NYGC'S CHIEF DIAGNOSTICS OFFICER, THE PROJECT WILL SEQUENCE 10,000 PATIENTS WITH SCHIZOPHRENIA TO IDENTIFY RARE, STRUCTURAL, AND COMMON VARIANTS AND INVESTIGATE THEIR ROLE IN CLINICAL PREDICTIONS. COPPER AIMS TO ENABLE EARLY INTERVENTION AND SUPPORT, PAVING THE WAY FOR PRECISION PSYCHIATRY TAILORED TO INDIVIDUAL NEEDS. FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) GENOMIC TECHNOLOGY: THIS YEAR, THE NYGC TECHNOLOGY INNOVATION LAB HAS FOCUSED SIGNIFICANT EFFORTS ON ADVANCING SPATIAL GENOMICS AND MOLECULAR PROFILING TECHNOLOGIES. THROUGH INNOVATIVE PROJECTS LIKE MICROST, SPATIAL CUT&TAG, AND THE DEVELOPMENT OF THE CSPLOTCH ALGORITHM, THE TEAM IS DELIVERING TOOLS THAT ENHANCE OUR UNDERSTANDING OF GENE EXPRESSION, CELLULAR COMPOSITION, AND TISSUE-SPECIFIC GENE REGULATION. THESE PROJECTS ARE NOT ONLY EXPANDING THE AVAILABLE RESEARCH TOOLKIT AND CAPABILITIES IN THE FIELD, BUT ALSO REVEALING NEW INSIGHTS INTO THE MOLECULAR MECHANISMS UNDERLYING COMPLEX BIOLOGICAL PROCESSES, AGING, AND DISEASE - INSIGHTS THAT MAY PAVE THE WAY FOR FUTURE THERAPEUTIC BREAKTHROUGHS. THE NYGC HAS BUILT AN IMPRESSIVE GENOMIC TECHNOLOGY AND SEQUENCING INFRASTRUCTURE, ENABLING HIGH-THROUGHPUT NEXT-GENERATION SEQUENCING WITH ROBUST ANALYTICS AND BROAD ACCESS TO CUTTING-EDGE TECHNOLOGIES TO THE NEW YORK RESEARCH COMMUNITY. THE NYGC PRODUCTION SEQUENCING LAB HAS BEEN GENERATING SEQUENCING DATA FOR A LARGE NUMBER OF PROJECTS AND A DIVERSE SET OF INVESTIGATORS FROM THROUGHOUT THE NEW YORK CITY COMMUNITY AND BEYOND, INCLUDING FOR MAJOR NIH GRANTS AND FOR THE BRAIN INITIATIVE CELL ATLAS NETWORK (BICAN), PRIMARILY IN COLLABORATION WITH THE ALLEN INSTITUTE IN SEATTLE. THE LAB HAS SEQUENCED NEARLY 200 ILLUMINA FLOW CELLS (NEARLY 3 TRILLION SEQUENCING READS), GENERATING LARGE SCALE SINGLE CELL AND MULTIOMIC DATA FOR THE ATLAS. THE CENTER REMAINS AT THE FOREFRONT OF HIGH-QUALITY SEQUENCING AT SCALE THROUGH EARLY AND STRATEGIC INVESTMENT IN THE LATEST TOOLS AND TECHNOLOGIES. CLINICAL LABORATORY: NYGC HOUSES A STATE-OF-THE-ART CLINICAL DIAGNOSTIC LABORATORY THAT UTILIZES NEXT-GENERATION SEQUENCING TECHNOLOGY TO PERFORM ADVANCED TESTS IN GENETICS AND ONCOLOGY. THIS LAB IS FOUNDATIONAL TO NYGC'S ABILITY TO DELIVER RAPID, HIGH-QUALITY CLINICAL GENOMIC SERVICES THAT ARE DIRECTLY SHAPING PATIENT CARE. ONE OF NYGC'S FLAGSHIP INITIATIVES IS THE WOMEN'S GENETICS CENTER (WGC), LAUNCHED IN PARTNERSHIP WITH NEW YORK-PRESBYTERIAN HOSPITAL AND COLUMBIA UNIVERSITY IRVING MEDICAL CENTER. THIS COLLABORATION IS DEDICATED TO CHANGING WOMEN'S HEALTHCARE THROUGH THE CLINICAL APPLICATION OF GENOME SEQUENCING (GS). THE WGC IS DEVELOPING AFFORDABLE, ROUTINE GS-BASED TESTS FOR WOMEN SEEKING GENETIC CONSULTATION FOR PREGNANCY PLANNING, FETAL ANOMALIES, AND PRENATAL GENETIC TESTING. THE GOAL IS TO EVENTUALLY REPLACE TRADITIONAL TESTS, SUCH AS KARYOTYPING, CHROMOSOMAL MICROARRAYS, AND PANEL OR EXOME SEQUENCING, WITH MORE COMPREHENSIVE, COST-EFFECTIVE GS SOLUTIONS. COMMUNITY: IN SUPPORT OF NYGC'S VISION AND VALUES, NYGC IS COMMITTED TO FOSTERING COMMUNITY AND A CULTURE OF BELONGING, SHARED PURPOSE, AND MUTUAL RESPECT. THE ORGANIZATION HAS BEEN WORKING TO HELP EMPLOYEES FEEL CONNECTED TO THEIR WORK AND THE CENTER'S CORE VALUES, WHILE BUILDING A STRONG SENSE OF COMMUNITY. OUR GOAL IS TO ENSURE THAT EVERY COMMUNITY MEMBER FEELS REPRESENTED, RESPECTED, SUPPORTED, AND TREATED WITH DIGNITY, WHILE CELEBRATING THEIR UNIQUE BACKGROUNDS, TALENTS, AND PERSPECTIVES. FORM 990, PART VI, SECTION A, LINE 2 NYGC BOARD MEMBERS ELI CASDIN, ANTHONY EVNIN, THOMAS MANIATIS, AND NANCY THORNBERRY HAVE A BUSINESS RELATIONSHIP, EITHER DIRECTLY OR INDIRECTLY, THROUGH KALLYOPE, INC., A BIOTECHNOLOGY COMPANY DEVELOPING ORAL THERAPEUTICS AGAINST METABOLIC, NEUROLOGICAL, AND GASTROINTESTINAL DISEASES. NYGC HAS NOT CONDUCTED ANY BUSINESS WITH KALLYOPE, INC. FORM 990, PART VI, SECTION A, LINE 6 ORGANIZATION MEMBERS AS OF DECEMBER 31, 2024, THE CENTER HAD A TOTAL OF 13 MEMBERS, CONSISTING OF TEN INSTITUTIONAL FOUNDING MEMBERS AND THREE ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL, AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) ROCKEFELLER UNIVERSITY (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, AND (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, AND (3) HACKENSACK MERIDIAN HEALTH. FORM 990, PART VI, SECTION A, LINE 7A ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR/CEO AND INDEPENDENT DIRECTORS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS, AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER, GENERAL COUNSEL, AND THE SCIENTIFIC DIRECTOR & CEO, REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. PRIOR TO FILING, MANAGEMENT ALSO PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION REVIEW AND APPROVAL FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2024, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN JANUARY 2024 AND APPROVED THE 2024 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM DID NOT RECEIVE MERIT INCREASES IN 2024. FORM 990, PART VI, SECTION C, LINE 19 DOCUMENT AVAILABILITY NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A IN 2024, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVE AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINED A LABORATORY AND CONDUCTED INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.